Nouscom raises €120M Series D to intercept cancer before it starts

Nouscom has raised a €120M ($135M) oversubscribed Series D co-led by M Ventures and Revelation Partners to take NOUS-209, its off-the-shelf cancer-interception immunotherapy for Lynch syndrome carriers, into a single global registration-enabling trial – the Basel company announced the round on 19 October.

European biotech has spent three years hearing that growth capital is the missing rung on our ladder – and yet this is the second nine-figure European biotech round to land in our records in five days. Below, I lay out the round, the decade of science it pays for, and why the passports in the syndicate are the quiet story.

A round built for one trial, not a pipeline

The €120M arrives with an unusually single-minded job description: fund one global, registration-enabling clinical trial of NOUS-209 for cancer interception in people with Lynch syndrome, the inherited condition that raises lifetime colorectal and endometrial cancer risk to as much as 50%, against 1-2% in the general population (company announcement, 19 October). The US FDA has already granted the programme Fast Track designation.

M Ventures, the corporate venture arm of Germany’s Merck KGaA, and Revelation Partners, the US healthcare investor, co-led the oversubscribed round. New backers Angelini Industries (through Angelini Investments), the European Investment Bank (through Aurea, its co-investment facility with Angelini Ventures) and Neva SGR, the venture arm of Intesa Sanpaolo, joined. Existing investors returned in force: 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance through its InnoBio2 fund, CDP Venture Capital through its Large Ventures Fund, EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures and XGEN Ventures.

The loyalty is measurable. Nouscom’s €67.5M Series C in November 2023 was co-led by Andera Partners, Bpifrance and M Ventures, with Revelation Partners participating (Walder Wyss deal record, November 2023). Three years later, the participant has become a co-lead. “What sets Nouscom apart is its unique cancer interception approach,” said Hakan Goker, managing director and head of biotechnology investments at M Ventures, in the announcement.

Vaccinating against a tumour that does not exist yet

Nouscom, founded in 2015 and running research and manufacturing out of Basel and Rome, builds viral-vectored immunotherapies around neoantigens – the mutated protein fragments that flag a cancer cell to the immune system. NOUS-209, its lead asset, packs 209 shared frameshift neoantigens into two proprietary viral vectors, training T cells to recognise the signature mutations of tumours with mismatch repair deficiency and microsatellite instability.

The data behind this round’s conviction goes public this week. In the Phase 1b/2 study, every evaluable Lynch syndrome carrier remained free of advanced adenomas and colorectal cancer after year one (43 carriers) and year two (17), with T-cell responses that strengthened after annual re-treatment (company announcement; the full dataset is an oral presentation at ESMO in Madrid on 25 October). For a condition managed today by surveillance colonoscopy and pre-emptive surgery, an off-the-shelf vaccine is a different proposition altogether.

The market is sized for treatment, not prevention

The global cancer vaccines market is put at $8.3bn in 2025, heading for $19.4bn by 2034 at a 9.62% CAGR over 2026-2034 (IMARC Group, August 2026). The honest caveat: nearly all of that figure is therapeutic – vaccines given to people who already have cancer. No reliable sizing exists for cancer interception in healthy high-risk carriers, because no such product has ever been approved. Nouscom is raising against a market its trial would have to create.

For scale against our own October records: OMass Therapeutics’ €276.1M Series C in Oxford (15 October) and Microbiotica’s £36M Series C first close in Cambridge (16 October) bracket this round. Europe’s clinical-stage companies are suddenly raising at sizes we spent 2024 insisting only Boston could support.

Count the Italian flags in a Swiss round

So who is actually writing Europe’s late-stage biotech cheques? Scan this syndicate: Angelini Industries, Angelini Ventures, CDP Venture Capital, Neva SGR, Indaco, Panakes, XGEN – a column of Italian institutions in one Basel round, alongside the EU’s own bank. It is not sentiment. Nouscom’s research and manufacturing sit partly in Rome, and Italian institutional capital is following the science across the border, showing up exactly where US crossover funds would sit in a Boston syndicate.

The good news is that this looks like a pattern, not an exception: state-anchored and corporate capital – British Business Bank leading in Cambridge last week, Bpifrance re-upping here, Merck’s venture arm co-leading – is doing the job Europe’s missing growth funds left vacant. What to watch now: the ESMO readout on 25 October, the registration trial’s first patient, and whether cancer interception starts appearing as its own line in European life-science fund theses.

Europe does not lack the science to stop cancer before it starts – it has just funded a decade of it, from Basel to Rome. Watch the Madrid data on Sunday, then watch who follows the Italians in. The full map of who is funding European biotech this quarter is in our fundraising data.